CompoAtlas

Devigest

Devigest, licence 80042319: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names
Devigest ADS
Licence holder
Arthur Andrew Medical Inc.
NPN or DIN-HM
80042319
Status
Active licence
Licence date
16 May 2013
Revision date
11 April 2022
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
1,4-alpha-D-Glucane glucohydrolase

Source : Aspergillus flavus var. oryzae

25.0 FCC AGUNot calculated
1,4-alpha-D-Glucane glucohydrolase

Source : Aspergillus flavus var. oryzae

20.84 mgNot calculated
alpha-D-Galactoside galactohydrolase

Source : Aspergillus niger

150.0 FCC GalUNot calculated
alpha-D-Galactoside galactohydrolase

Source : Aspergillus niger

12.5 mgNot calculated
1,3-bêta-D-xylane xylanohydrolase

Source : Trichoderma longibrachiatum

250.0 FCC XUNot calculated
Protéase

Source : Aspergillus flavus var. oryzae

26.32 mgNot calculated
Protéase

Source : Aspergillus niger

25250.0 FCC HUTNot calculated
Protéase

Source : Aspergillus niger

26.32 mgNot calculated
Protéase

Source : Aspergillus flavus var. oryzae

10250.0 FCC HUTNot calculated
Protéase

Source : Aspergillus flavus var. oryzae

37.31 mgNot calculated
Protéase

Source : Aspergillus flavus var. oryzae

250.0 DPP-IVNot calculated
Bêta-D-galactoside galactohydrolase

Source : Aspergillus flavus var. oryzae

1000.0 FCC ALUNot calculated
Protéase

Source : Aspergillus flavus var. oryzae

25250.0 FCC HUTNot calculated
alpha-L-arabinofuranoside arabinofuranohydrolase

Source : Trichoderma reesei

1000.0 FCC HCUNot calculated
alpha-L-arabinofuranoside arabinofuranohydrolase

Source : Aspergillus niger

1000.0 FCC HCUNot calculated

Non-medicinal ingredients

Maltodextrine, cellulose, Eau distillée

PopulationAgeQuantity per servingFrequency
AdultesNot specified2.0 Capsule3.0 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Alpha-galactosidase helps reduce flatulence following meals rich in fermentable carbohydrates. Alpha-galactosidase helps prevent gastrointestinal intolerance of oligosaccharides/fermentable carbohydrates. Digestive aid. Helps digest proteins. Digestive enzymes.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80042319

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2022. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line